z Given that these two PROs are commonly used but potentially not with the same patients, and each uses a different recall period, it is important to understand to what extent they provide a similar understanding of patients' disease severity, impact on HRQoL and their response to treatment.
− If researchers and clinicians have comparable understanding of a patient's condition and response to treatment regardless of which of these instruments is used to assess CSU/CIU, then there is greater confidence that either instrument will yield insights into the effects of CSU/CIU and its treatment on patients.
− Further, if a comparable understanding of a patient's condition and response to treatment can be obtained from a single assessment referring to the past week (DLQI), physicians could administer the DLQI in lieu of UAS7, especially when there are concerns about potential missing diary data or difficulties of UAS7 implementation in daily practice. The purpose of this analysis was to examine changes in a symptom-based instrument, the UAS7, with those of a dermatologic-specific HRQoL instrument, the DLQI, to see if the DLQI could be used in a single clinic visit in lieu of collecting UAS7 diary data.
METHODS

Data
z Data come from three pivotal, phase III clinical trials (ASTERIA I, ASTERIA II, GLACIAL) investigating the effects of omalizumab for patients with refractory CSU/CIU (Maurer 2013 ).
z Treatment was administered once every 4 weeks until 24 weeks in the 40-week trials (ASTERIA I and GLACIAL), and until 12 weeks in the 28-week trial (ASTERIA II).
z In all trials there was a 16-week follow-up period with no active treatment.
z DLQI data were collected at − Baseline and weeks 4, 12, 24, and 40 in two trials (ASTERIA I and GLACIAL), and − Baseline and weeks 4, 12, and 28 (ASTERIA II) z UAS7 scores were reported at baseline and every four weeks. UAS7 data from the same weeks as the DLQI were used for these analyses.
Analytic Methods
z Data from all 3 studies were analysed using a growth curve analysis known as latent growth modelling to evaluate change across all assessment points for each patient, irrespective of treatment, and compare change in one variable with change in another.
z Unlike analyses that compare mean changes between groups of patients, latent growth models (LGMs) calculate an intercept and slope of change for each patient for each PRO and allow the intercepts and slopes of change to be correlated (Stull, 2008) .
z This indicates the extent to which change in a patient's DLQI score is associated with change in their UAS7 score. The greater the correlation between a patient's slopes of change in DLQI and UAS7, the greater the similarity in what these two instruments are assessing.
RESULTS
z Across all three trials, the correlation between slopes of change in DLQI and UAS7 scores was very high (r = 0.88 -0.94), indicating that the trajectory of change in a patient's score on the DLQI very closely matches that of the UAS7 score.
− That is, if a patient's score on the DLQI changed 1 standardized point, their score on the UAS7 changed nearly the same standardized amount.
z Increases in both UAS7 and DLQI can be seen in the follow-up period after week 24 (ASTERIA I and GLACIAL) and week 12 (ASTERIA II), after treatment ended.
z Figure 1 presents these results for ASTERIA I; Figure 2 presents these results for ASTERIA II; Figure 3 presents these results for GLACIAL. 
CONCLUSIONS
z The results of these latent growth models give clear and compelling evidence that the UAS7, a daily diary summed over seven days, and the DLQI, a brief, single assessment of HRQoL referring to the previous week, showed nearly identical responses:
